References
- Yamada S , TangM, RichardsonK et al.: Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.Pharmacogenomics10 , 1433–1445 (2009).
- Benichou C : Criteria of drug-induced liver disorders: report of an international consensus meeting.J. Hepatol11 , 272–276 (1990).
- American Thoracic Society: Hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med.174 , 935–952 (2006).
- Solus JF , AriettaBJ, HarrisJR et al.: Genetic variation in eleven Phase I drug metabolism genes in a ethnically diverse population.Pharmacogenomics5 , 895–931 (2004).
- Vuilleumier N , RossierMF, ChiappeA et al.: CYP2E1 genotype and isoniazid-induced hepatotoxiciy in patients treated for latent tuberculosis.Eur. J. Clin. Pharmacol.62 , 423–429 (2006).
- Huang YS , ChernHD, SuWJ et al.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.Hepatology37 , 924–930 (2003).
- Leiro V , Fernández-VillarA, ValverdeD et al.: Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population.Liver Int.28 , 835–839 (2008).
▪ Website
- Human Cytochrome P450 Allele Nomenclature Committee www.cypalleles.ki.se/index.htm.